DEVENDRA SHAH: Open Payments
NPI 1164418125 · MONROE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,181 in 77 payments from 16 companies in 2025. Trend: 2023 $2,301 · 2024 $2,478 · 2025 $2,181
Food & beverage: $2,181
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 9 | $424 |
| Otsuka America Pharmaceutical, Inc. | 11 | $282 |
| Vanda Pharmaceuticals Inc. | 9 | $231 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $210 |
| E.R. Squibb & Sons, L.L.C. | 5 | $190 |
| Neuronetics, Inc. | 1 | $172 |
| Janssen Pharmaceuticals, Inc | 5 | $162 |
| Lundbeck LLC | 5 | $98 |
| Teva Pharmaceuticals USA, Inc. | 4 | $79 |
| Bausch Health US, LLC | 4 | $66 |
Products named: INGREZZA, REXULTI, FANAPT, CAPLYTA, COBENFY, NEUROSTAR TMS THERAPY SYSTEM, INVEGA SUSTENNA, ABILIFY ASIMTUFII.
Industry payments across NC — which companies pay providers there.
